Schreiner MediPharm, a Germany-based global provider of functional label solutions for the healthcare industry, has introduced a novel solution for the digital marking of investigational drugs during clinical trials. The company’s Digital Display Label allows trial sponsors to eliminate time-consuming manual relabeling, enabling substantial process optimization and helping shorten a drug’s time to market.

Schreiner MediPharm’s new Digital Display Label comprises a modular, reusable plastic housing that reliably protects sensitive display electronics. A carefully conceived adapter system ensures ease of integration into a variety of packaging formats, including flat blister wallets and kit boxes or round containers like plastic bottles and vials. For transparent containers, additional features such as light protection or blinding can be integrated.

Among the Digital Display Label’s key benefits is the ability to update label information digitally and in real time. As a result, patients and clinical trial personnel consistently receive current information concerning the investigational drug, without delays or additional materials or logistics costs.

Schreiner MediPharm’s Digital Display Label also brings attractive sustainability advantages. Because the solution’s housing and adapter system are reusable, resources are conserved and waste is avoided. The modular design enables integration into existing standard packaging without requiring modifications, further streamlining overall efficiencies. At the same time, the system ensures a reliable connection between the Digital Display Label and the primary container or packaging.

Overall, Schreiner MediPharm’s Digital Display Label not only enhances efficiency in clinical trial logistics but also accelerates the entire trial process while offering pharmaceutical companies and contract research organizations (CROs) significant savings potential and higher patient compliance – a significant stride toward modern, digital clinical trial procedures.